Cost–utility analysis and drug pricing of once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes patients treated with basal insulin in China
Authors' conclusion
Insulin icodec appears to be more cost effective than degludec if the annual cost of icodec ranges from $597.66 to $736.34 for patients with type 2 diabetes in China.
Study context
- Population
- Simulated T2D patients treated with basal insulin in China; efficacy and safety data from the ONWARDS 2 trial
- Comparison
- Once-weekly insulin icodec vs once-daily insulin degludec
- Outcome
- Price range (annual cost) of icodec at which it is cost effective vs degludec
- Follow-up
- 40 years
Methodological detailsUKPDS Outcomes Model (version 2.1) simulation, 40-year horizon, Chinese healthcare provider's perspective, binary search, one-way, probabilistic and scenario sensitivity analyses
- UKPDS Outcomes Model (version 2.1) simulation
- 40-year horizon
- Chinese healthcare provider's perspective
- Binary search
- One-way, probabilistic and scenario sensitivity analyses
Main finding
As reported in the abstract
Cost-effective annual cost range of icodec
Annual cost range of icodec after binary search
$625.17-$855.25
Annual cost range of icodec adjusted by one-way sensitivity analysis, confirmed by probabilistic sensitivity and scenario analysis
$597.66-$736.34
Further findings
QALYs · 40 years
Cost-utility at equal annual costs of $455.40
- Icodec dominant vs degludec, with higher quality-adjusted life years (QALYs) and lower total cost
Scenario: degludec price decreased by 20%
- Annual cost range of icodec
- $506.70-$736.34
Original publication
Cost–utility analysis and drug pricing of once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes patients treated with basal insulin in China. Diabetes Obes Metab. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →